Form 4 for TLSI TriSalus Life Sciences, Inc.
Accepted 2026-07-01 16:04:47 ET · period of report 2026-06-30 · accession 0001628280-26-046519 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 16:04 | 2026-06-30 | TLSI | Szela Mary T | CEO, Pres, Dir | A - Grant | $3.87 | +3,990 | 1.08M | +0.4% | +$15.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | A | A | 3,990 | $3.87 | 1,077,683 | D | — | — | (F1) Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. |